Walleye Capital
CCCC icon

Walleye Capital’s C4 Therapeutics CCCC Stock Holding History

Walleye Capital’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-300
Closed -$573 – 4449
2025
Q4 		$573 Buy
+300
New +$711 ﹤0.01% 4399
2024
Q2 		– Sell
-14,900
Closed -$122K – 5625
2024
Q1 		$122K Buy
+14,900
New +$115K ﹤0.01% 4282

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Walleye Capital's CCCC Position: Q2 2026 in Review

Walleye Capital reduced its C4 Therapeutics (CCCC) stake by 52% in Q2 2026, selling an estimated $424K and leaving 115,125 shares worth $538K. The position accounts for ﹤0.01% of the portfolio, ranked #2656.

Walleye Capital first reported a position in CCCC in Q4 2021 and has held it in 11 quarters since. The position peaked at $2.63M in Q4 2021. 147 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • Walleye Capital held 115,125 shares of C4 Therapeutics worth $538K as of Q2 2026.
  • Walleye Capital sold 123,993 C4 Therapeutics shares in Q2 2026, an estimated $424K.
  • C4 Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #2656 holding.
  • Walleye Capital first reported a position in C4 Therapeutics in Q4 2021 and has held it in 11 quarters since.
  • Walleye Capital's C4 Therapeutics position peaked at $2.63M in Q4 2021.
  • 147 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.